LB Pharmaceuticals Stock (NASDAQ:LBRX)

Forecast Ownership Financials Chart

Previous Close

$42.46

52W Range

$14.40 - $50.16

50D Avg

$40.28

200D Avg

$33.47

Market Cap

$1.34B

Avg Vol (3M)

$362.09K

Beta

0.42

Div Yield

-

LBRX Company Profile

This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

27

IPO Date

Sep 11, 2025

Website

LBRX Performance

LBRX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-64.83M	$-11.38M	$-2.81M
Net Income	$-63.10M	$-6.28M	$-14.35M
EBITDA	$-63.01M	$-1.45M	$-12.19M
Basic EPS	$-17.83	$-1.77	$-4.05
Diluted EPS	$-17.83	$-1.77	$-4.05

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
MPLT	MapLight Therapeutics, Inc.
GHRS	GH Research PLC
NMRA	Neumora Therapeutics, Inc. Common Stock
DNLI	Denali Therapeutics Inc.
RAPP	Rapport Therapeutics, Inc. Common Stock
ACAD	Acadia Pharmaceuticals Inc.
SPTX	Seaport Therapeutics, Inc. Common Stock
NERV	Minerva Neurosciences, Inc.
DFTX	Definium Therapeutics, Inc.
ANRO	Alto Neuroscience, Inc.